CDE Adds Two New Drugs to Rare Disease “Caring Program – Extension” Pilot – SZJ0107 and JAB-8263 Included
According to the latest announcement from the Center for Drug Evaluation (CDE) of the National...
Jacobio Pharmaceuticals
Jacobio Pharmaceuticals’ JAB-8263 BET Inhibitor Proposed for NMPA’s Rare Disease “Caring Program” for Myelofibrosis Treatment
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) announced that...
Jacobio Launches Phase Ib/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca
Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) announced that the first patient has been dosed...
Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)
Jacobio Pharmaceuticals (HKG: 1167) announced that its portfolio company, Jacobio-Raikang, has received National Medical Products...
Jacobio Pharma, Oceanpine Capital and Partner Acquire Majority of Jacoray, Fuelling Early‑Stage Cardio‑Oncology R&D
Jacobio Pharma Ltd. (HKG: 1167) announced today that its subsidiary Beijing Jacobio Pharmaceuticals Co., Ltd....
Jacobio Pharmaceuticals Secures 80% Equity Investment in Jacoray from Oceanpine Capital
Jacobio Pharmaceuticals (HKG: 1167) today announced a capital‑increase and equity‑transfer agreement that will see Shanxi...
Jacobio Pharma Initiates First Patient Dosing in U.S. Phase I/IIa Study for Pan-KRAS Inhibitor JAB-23E73
China-based Jacobio Pharma (HKG: 1167) announced the first patient dosing of a Phase I/IIa study...
Jacobio Pharma’s Glecirasib Approved by NMPA for KRAS G12C+ NSCLC
China-based Jacobio Pharma (HKG: 1167) announced that it has received marketing approval from the National...
Jacobio Pharma’s BET Inhibitor JAB-8263 Shows Promising Results in Myelofibrosis Phase I Study
Jacobio Pharma (HKG: 1167) has announced the presentation of preliminary results from the Phase I...
Jacobio Pharma’s G12C Inhibitor Gecirasib Earns Orphan Drug Designation in Europe for Pancreatic Cancer
Jacobio Pharma (HKG: 1167), a China-based biopharmaceutical company, has announced that it has received Orphan...
Jacobio Pharma Receives NMPA Approval for Pan-KRAS Inhibitor JAB-23E73 Clinical Trial
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has received approval from the...
Jacobio Pharma Receives RMB 172 Million Milestone Payment from Allist Pharmaceuticals
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the receipt of...
Jacobio Pharma’s Pan-KRAS Inhibitor JAB-23E73 Clears FDA Hurdle for Clinical Trials
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has received the green light...
Allist Pharmaceuticals Acquires Jacobio’s G12C Inhibitor and SHP2 Inhibitor Rights for Greater China Region
SHANGHAI—Allist Pharmaceuticals Co., Ltd, a Shanghai-based biotech company, has entered into a licensing agreement with...
Jacobio Pharma’s KRAS G12C Inhibitor Combo Shows Promising Results in NSCLC at ASCO 2024
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, presented updated data at the...
Jacobio Pharma’s Gecirasib Gets Priority Review for NSCLC Treatment by China’s NMPA
Jacobio Pharma (HKG: 1167), a leading biopharmaceutical company based in China, has announced that its...
Jacobio Pharma’s KRAS G12C Inhibitor Gains NMPA Approval for Phase III CRC Study
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced that it has...
Jacobio Pharma Applies for Approval of KRAS G12C Inhibitor Gecirasib in China
Jacobio Pharma (HKG: 1167), a China-based biopharmaceutical company, has announced the submission of a New...
Jacobio Pharma’s Glecirasib Shows Promise in Phase II Study for NSCLC Presented at ASCO
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the presentation of...
Jacobio Pharma Gets CDE Green Light for Phase III Study Combining Gleevec Inhibitors in NSCLC
Jacobio Pharma (HKG: 1167), a China-based pharmaceutical company, has announced that it has received approval...